From Jakob Passweg (Activity Survey Clinical Advisor) and Helen Baldomero (Activity Survey Coordinator)
We hope you are your team are in good health. With the ongoing SARS-CoV-2 pandemic, we would like to thank you for your excellent collaboration last year and the continued reporting of your annual transplant activity data despite the extremely difficult situation we have all experienced these last two years. We are currently analysing the 2020 data and hope to submit it for publication before the end of December.
This current survey request to report your 2021 activity is again of great importance. We plan to continue our assessment on whether transplant rates have been altered by the SARS-CoV-2 or whether the emergence of novel cellular therapies has influenced the transplant numbers in any way.
We would be grateful if you could submit your data promptly.
To do so, you can download the survey sheet below or go to the Transplant Activity Survey section. When reporting your data please note the following:
Reporting guidelines: Table 1 for HSCT
Rows 1-28, 1st HSCT: report the number of first allograft and /or first autograft in 2021 for both pediatric and adult patients. E.g., a patient with two autologous HSCT is counted as one first transplant and one additional transplant. A patient with an allograft following an autograft is counted as 1 x first allograft and 1 x first autograft.
Row 29: is the sum of rows 1 - 28.
Row 30: is for reporting the number of additional second/third transplants.
Row 31: is the sum of rows 29 + 30.
Row 32: is for reporting the total number of pediatric transplants (<18 at transplant) also reported in rows 1-28.
Row 34: report the number of patients receiving their first unmanipulated DLI in 2021 and main reason for giving it. E.g., if a patient receives three DLI infusions in 2021; report as one patient.
Table 2 for Cellular therapies: Report the number of patients receiving NON HSCT cell therapies using manipulated or selected cells in your centre in 2021 by indication and donor type. Report the number of patients and not the number of infusions: E.g., a patient with three NK infusions is counted as one patient. Cell therapies can be reported within or outside of the context of HSCT.
Please also report patients treated in clinical trials, as this survey does not affect any confidentiality issues and provides an overview of how many therapies are performed in Europe each year.
The guidelines will help with reporting your data as well. You may return your survey using the self-addressed envelope included in the postal mailing you will have recently received or by e-mail to firstname.lastname@example.org
If you do not have any data to report to the 2021 survey, please let us know by returning this letter and indicate the reason when possible.
We would be grateful if you could submit your 2021 data by 1st April 2022.
Thank you and with our best regards